CEPP

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

CEPP is an acronym for the name of a chemotherapy regimen that is intended for treatment of aggressive Non-Hodgkin Lymphomas. Unlike CHOP, this chemotherapy regimen does not contain doxorubicin or any other anthracycline. Thus, it can be used in patients with severe cardiovascular diseases and contraindications for doxorubicin-containing regimens. There are 2 modifications of CEPP - with the addition of bleomycin, called CEPP (B), and without bleomycin - ordinary CEPP.[1]

This regimen also does not contain vincristine and can be used in patients with neuropathy.

In combination with anti-CD20, monoclonal, antibody, and rituximab. this regimen is called R-CEPP(B).

[R]-CEPP(B) regimen consists of:

  1. (R)ituximab - a monoclonal antibody that is able to kill CD20-positive B cells, either normal or malignant;
  2. (C)yclophosphamide - an alkylating antineoplastic agent;
  3. (E)toposide - a topoisomerase inhibitor from the epipodophyllotoxin group;
  4. (P)rocarbazine - an alkylating antineoplastic agent;
  5. (P)rednisone or (P)rednisolone - a glucocorticoid hormone that has the ability to cause apoptosis and lysis of lymphocytes, either normal or malignant;
  6. (B)leomycin - an antitumor antibiotic.

Dosing regimen[edit]

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(C)yclophosphamide 600 mg/m2 IV infusion Days 1 and 8
(E)toposide 70 mg/m2 IV infusion Days 1-3
(P)rocarbazine 60 mg/m2 PO qd Days 1-10
(P)rednisone or (P)rednisolone 60 mg/m2 PO qd Days 1-10
(B)leomycin 10 IU/m2 IV bolus Day 1

References[edit]